Treatment(s) now being considered-Hormonal therapy Posts on Medivizor
Navigation Menu

Treatment(s) now being considered-Hormonal therapy Posts on Medivizor

Should androgen-deprivation therapy be given at the same time or before radiotherapy in the treatment of localized prostate cancer?

Should androgen-deprivation therapy be given at the same time or before radiotherapy in the treatment of localized prostate cancer?

Posted by on Jun 11, 2020 in Prostate cancer | 0 comments

In a nutshell The study looked at the sequence of dose-escalated radiotherapy (RT) and androgen-deprivation therapy (ADT) in the treatment of local prostate cancer (LPCa). The study found that treatment with ADT before RT had the same outcome as treatment with ADT and RT at the same time.  Some background LPCa is a form of cancer that is...

Read More

How effective are therapies to prevent bone loss in patients with breast cancer?

How effective are therapies to prevent bone loss in patients with breast cancer?

Posted by on May 30, 2020 in Breast cancer | 0 comments

In a nutshell This study examined the effectiveness of three commonly used therapies to prevent bone loss in patients with hormone-positive breast cancer (BC). The results showed that the therapies prevented bone loss and fractures but to different degrees. Some background Many patients with BC are classified as hormone-positive. This means...

Read More

Evaluating the impact of long term androgen deprivation therapy and radiotherapy after prostate surgery in patients with high risk of relapse

Posted by on Apr 30, 2020 in Prostate cancer | 0 comments

In a nutshell The study looked at the effects of long term androgen deprivation therapy (LT-ADT), pelvic lymph node radiotherapy (PLNRT) and prostate bed radiotherapy (PBRT) in patients with prostate cancer and high risk of recurrence after prostate surgery. They found an increase in survival without cancer worsening in these patients.  Some...

Read More

Evaluating docetaxel plus hormone therapy for the treatment of metastatic prostate cancer

Posted by on Nov 3, 2019 in Prostate cancer | 0 comments

In a nutshell This study evaluated the long-term outcomes of docetaxel (Taxotere) plus hormone therapy for patients with metastatic prostate cancer (cancer that spread outside the prostate). This study found that this treatment combination improved survival for these patients, regardless of tumor burden. Some background One treatment for...

Read More

Is there a link between anti-androgen therapy and depression in men treated for prostate cancer?

Posted by on Mar 29, 2019 in Prostate cancer | 0 comments

In a nutshell This study examined if anti-androgen therapy for prostate cancer is associated with depression. This study concluded that the risk of depression is increased in these patients.  Some background Anti-androgen therapy or androgen deprivation therapy (ADT) is commonly used in the treatment of prostate cancer. Androgens (such as...

Read More

Evaluating optimal duration of androgen deprivation therapy in high risk prostate cancer

Posted by on Nov 25, 2018 in Prostate cancer | 0 comments

In a nutshell This study aimed to investigate the effect of the length of androgen deprivation therapy (ADT) when used with radiotherapy in patients with prostate cancer. This study found that 18 months ADT led to similar overall survival and better quality of life as compared to 36 months in these patients.  Some background...

Read More

Comparing two hormone therapy drugs in men with advanced, non-metastatic prostate cancer

Posted by on Nov 17, 2018 in Prostate cancer | 0 comments

In a nutshell This study aimed to compare two hormone therapies, gonadotropin-releasing hormone (GnRH) agonists and anti-androgen therapy (AA) in men with advanced, non-metastatic prostate cancer. This study found that the two therapies have similar outcomes, but by starting with AA treatment may reduce side effects associated with GnRH...

Read More

10 years of treatment vs 5 years of treatment with hormone therapy in patients with early stage breast cancer.

Posted by on Oct 22, 2018 in Breast cancer | 0 comments

In a nutshell This study wanted to find out if continuing hormone therapy for 10 years was more effective than doing it for 5 years in patients with early stage breast cancer. The study found that the patients who continued treatment for 10 years survived for longer without the disease coming back compared to those who were only treated for 5...

Read More

Looking for patients with prostate cancer who have had a rise in PSA after prostate removal surgery

Posted by on Aug 31, 2018 in Prostate cancer | 0 comments

In a nutshell This trial is examining the effectiveness of different hormone therapy regimes for patients whose prostate specific antigen (PSA; a protein elevated in prostate cancer) levels rise after prostate removing surgery. The main outcome to be measured will be the change in PSA levels.   The details The best standard treatment...

Read More

Should men with castration-resistant metastatic prostate cancer receive further hormone therapy?

Posted by on Aug 21, 2018 in Prostate cancer | 0 comments

In a nutshell This study aimed to discover the optimal timing of hormone therapies in combination with androgen-deprivation therapy (ADT) for patients with metastatic hormone-sensitive prostate cancer. This study found that treatment with a second hormone therapy after prostate cancer becomes immune to hormone treatment is associated...

Read More

Breast cancer treatment with Tamoxifen and its relation to Fatty Liver Disease

Posted by on Aug 19, 2018 in Breast cancer | 0 comments

In a nutshell This study looked at the risk factors and protective factors surrounding non-alcoholic fatty liver disease in relation to tamoxifen (Novaldex) therapy for women with breast cancer. The authors found that a high BMI was a risk factor for tamoxifen related fatty liver disease, while exercise was a protective factor. Some background...

Read More